Drugs / MK-0873
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01235728 | Nov 2010 → Apr 2011 | psoriasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01140061 | May 2010 → Mar 2011 | psoriasis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00132769 | Jan → Nov 2005 | rheumatoid arthritis | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 2 | NCT00132730 | Jun 2004 → Aug 2005 | chronic obstructive pulmonary disease | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-0873 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01235728 ↗ |
| Modality | Small molecule | — CHEMBL485629 ↗ |
| Route | Oral | “a once-daily oral medication (MK-0873)” NCT00132730 ↗ |